This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
90
California Clinical Trials Medical Group
Glendale, California, United States
RECRUITINGOccurrence of Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 16 weeks
Severity of TEAEs
Time frame: Up to 16 weeks
REGN20934 concentration in serum
Time frame: Up to 16 weeks
Occurrence of Anti-Drug Antibodies (ADAs) to REGN20934
Time frame: Up to 16 weeks
Magnitude of ADAs to REGN20934
Time frame: Up to 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.